- Home
- NERV vs EQS Comparison
NERV vs EQS Comparison
Compare NERV & EQS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- EQS
- Stock Information
- Founded
- NERV 2007
- EQS 1991
- Country
- NERV United States
- EQS United States
- Employees
- NERV N/A
- EQS N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- EQS Finance Companies
- Sector
- NERV Health Care
- EQS Finance
- Exchange
- NERV Nasdaq
- EQS Nasdaq
- Market Cap
- NERV 16.0M
- EQS 14.9M
- IPO Year
- NERV 2014
- EQS N/A
- Fundamental
- Price
- NERV $2.23
- EQS $1.25
- Analyst Decision
- NERV Hold
- EQS
- Analyst Count
- NERV 1
- EQS 0
- Target Price
- NERV $5.00
- EQS N/A
- AVG Volume (30 Days)
- NERV 37.0K
- EQS 17.8K
- Earning Date
- NERV 02-20-2025
- EQS 01-01-0001
- Dividend Yield
- NERV N/A
- EQS N/A
- EPS Growth
- NERV N/A
- EQS N/A
- EPS
- NERV N/A
- EQS N/A
- Revenue
- NERV N/A
- EQS $1,137,000.00
- Revenue This Year
- NERV N/A
- EQS N/A
- Revenue Next Year
- NERV N/A
- EQS N/A
- P/E Ratio
- NERV N/A
- EQS N/A
- Revenue Growth
- NERV N/A
- EQS 1795.00
- 52 Week Low
- NERV $2.06
- EQS $1.01
- 52 Week High
- NERV $13.49
- EQS $1.95
- Technical
- Relative Strength Index (RSI)
- NERV 50.40
- EQS 58.81
- Support Level
- NERV $2.07
- EQS $1.01
- Resistance Level
- NERV $2.39
- EQS $1.37
- Average True Range (ATR)
- NERV 0.12
- EQS 0.12
- MACD
- NERV -0.01
- EQS 0.02
- Stochastic Oscillator
- NERV 48.48
- EQS 66.67
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.